[Form 4] Immunome, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Form 4 snapshot: On 07/29/2025 Immunome (IMNM) granted Chief Scientific Officer Jack Higgins an employee stock option for 196,000 common shares at a strike price of $10.60. The option expires on 07/28/2035, giving a standard 10-year term.

Vesting schedule: 25 % of the award vests on 07/29/2026; the remaining 75 % vests in equal monthly installments over the next 36 months, completing vesting by mid-2029.

Table I shows no purchases or sales of non-derivative shares, so Higgins’ direct common-stock position is unchanged. After the grant he beneficially owns 196,000 derivative securities, all held directly.

Investor takeaway: The filing records routine executive compensation; no immediate cash outlay occurred and potential dilution is limited to the new option pool.

Insights

Financial Analyst

TL;DR – Routine option grant with no immediate P&L or cash impact; neutral for valuation.

This Form 4 discloses a standard equity incentive: 196k options at $10.60 issued to the CSO. No common shares changed hands, so float and insider ownership remain unaffected today. The strike sits near prevailing biotech option levels, suggesting market-aligned pricing. Because vesting extends four years and exercise is discretionary, dilution—if any—will be spread over time and tied to future share-price appreciation. Overall, the event is typical for talent retention and should not materially sway Immunome’s near-term valuation metrics.

Corporate Governance Expert

TL;DR – Governance-standard grant aligns executive incentives; neutral impact.

The option award follows common governance practice: a four-year vesting ramp encourages long-term value creation and discourages quick exits. Absence of performance hurdles leaves upside purely market-based, but that is customary for comparable biotech roles. No multiple-reporting persons are involved, and filing timeliness appears compliant. Consequently, the disclosure is procedurally sound and carries no red-flag governance implications.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Higgins Jack

(Last) (First) (Middle)

C/O IMMUNOME, INC.

18702 N. CREEK PARKWAY, SUITE 100

(Street)

BOTHELL WA 98011

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Immunome Inc. [ IMNM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
07/29/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$10.6	07/29/2025		A		196,000		(1)	07/28/2035	Common Stock	196,000	$0	196,000	D

Explanation of Responses:

1. 25% of the shares subject to the options vest on July 29, 2026, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter.

	/s/ Sandra Stoneman, Attorney-in-Fact	07/31/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction was reported for IMNM on 07/29/2025?

Jack Higgins received an employee stock option for 196,000 shares at a $10.60 strike price.

When do Jack Higgins’ Immunome options start and finish vesting?

25 % vests on 07/29/2026; the remaining 75 % vests monthly over the next 36 months, ending mid-2029.

Did the Immunome CSO buy or sell common stock in this filing?

No. Table I lists no purchases or sales of non-derivative securities.

How many derivative securities does Jack Higgins own after the grant?

He beneficially owns 196,000 stock options.

What is the expiration date of the new IMNM options?

The options expire on 07/28/2035.